Cvrx Inc. secured U.S. FDA approval for magnetic resonance-conditional labeling for its Barostim system, a neuromodulator that improves symptoms of patients with heart failure. With the latest ...

Privately held CVRx that has created an implantable device to treat high blood pressure announced Monday that it has named Philippe Wanstok to the newly created position of chief commercial officer.

MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term ...

CVRx's Barostim Neo treats high blood pressure and heart failure using pacemaker technology. Minneapolis-based CVRx's technology is another great example of pacemaker technology being used in areas of ...